284 De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet (1982) 2(8292):231-4. Benditt EP, Hoffman JS, Eriksen N, Parmelee DC, Walsh KA. SAA, an apoprotein of HDL: its structure and function. Ann N Y Acad Sci (1982) 389:183-9. Niederau C, Backmerhoff F, Schumacher B, Niederau C. Inflammatorymediators and acute phase proteins in patients with Crohn’s disease and ulcerative colitis. Hepatogastroenterology (1997) 44(13):90-107. Zhang G, Liu J, Wu L, Fan Y, Sun L, Qian F, et al. Elevated expression of serum amyloid A 3 protects colon epithelium against acute injury through TLR2-dependent induction of neutrophil IL-22 expression in a mouse model of colitis. Front Immunol (2018) 9:1503. Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid A protein compared with C-reactive protein, alpha-1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest (1987) 17(5):460-7. Plevy S, Silverberg MS, Lockton S, Stockfisch T, Croner L, Stachelski J, et al. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn’s disease, and ulcerative colitis patients. Inflamm Bowel Dis (2013) 19(6):1139-48. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 16(5):448-57. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn’s disease and experimental colitis in vivo. Nat Med (2000) 6(5):583-8. Chalaris A, Schmidt-Arras D, Yamamoto K, Rose-John S. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Dig Dis (2012) 30(5):492-9. Rose-John S, Mitsuyama K, Matsumoto S, Thaiss WM, Scheller J. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des (2009) 15(18):2095-103. Allocca M, Jovani M, Fiorino G, Schreiber S, Danese S. Anti IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets (2013) 14(12):1508-21. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol (1994) 56(5):559-64. Mahida YR, Ceska M, Effenberger F, Kurlak L, Lindley I, Hawkey CJ. Enhanced synthesis of neutrophilactivating peptide-1/interleukin-8 in active ulcerative colitis. Clin Sci (Lond) (1992) 82(3):273-5. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis (2005) 11(6):589-96. Neubauer K, Matusiewicz M, Bednarz-Misa I, Gorska S, Gamian A, Krzystek-Korpacka M. Diagnostic potential of systemic eosinophil-associated cytokines and growth factors in IBD. Gastroenterol Res Pract (2018) 2018:7265812. Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut (1986) 27(1):92-5. Zittan E, Kabakchiev B, Kelly OB, Milgrom R, Nguyen GC, Croitoru K, et al. Development of the HarveyBradshaw Index-pro (HBI-PRO) score to assess endoscopic disease activity in Crohn’s disease. J Crohns Colitis (2017) 11(5):543-8. Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis (2012) 18(9):1634-40. Solem CA, Loftus EV Jr, TremaineWJ, HarmsenWS, Zinsmeister AR, SandbornWJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 11(8):707-12. 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 Chapter 8
RkJQdWJsaXNoZXIy MjY0ODMw